Physician
Hematology
Dr. Chandra P. Belani, MD
|
|
Give Review
Chandra P. Belani is an expert in the field of Hematology. He researched medicine at Sawai Man Singh Medical College. He received 3 awards: "America's Top Doctors", "America's Top Doctors for Cancer" and "Pittsburgh Magazine". Dr. Chandra P. Belani is a published doctor as well. He has 100 publications published. The latest was: A patient with complex multiple genomic ALK alterations. Chandra P. Belani accepts Medicare.
Publications
- A patient with complex multiple genomic ALK alterations.
- Nodal stage of surgically resected non-small cell lung Cancer and its effect on recurrence patterns and overall survival.
- A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent.
- Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic Cancer.
- Targeted immunotherapy for non-small cell lung Cancer.
- Induction of autophagy contributes to crizotinib resistance in ALK-positive lung Cancer.
- Taxanes, past, present, and future impact on non-small cell lung Cancer.
- Endobronchial Valve Placement for Spontaneous Pneumothorax From Stage IIIA Non-Small Cell Lung Cancer Facilitates Neoadjuvant Therapy.
- Flexible Micro Spring Array Device for High-Throughput Enrichment of Viable Circulating Tumor Cells.
- Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study.
- Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell Lung ...
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer.
- Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung Cancer treated with resection or stereotactic radiosurg...
- Small-cell lung Cancer: an update on targeted therapies.
- Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung Cancer: an update.
- Recent clinical developments and rationale for combining targeted agents in non-small cell lung Cancer (NSCLC).
- A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California...
- Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer: An ...
- A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid Cancers: a ...
- Multidisciplinary management of Malignant pleural effusion.
- Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003).
- Cetuximab for the Treatment of Advanced Bronchioloalveolar Carcinoma (BAC): An Eastern Cooperative Oncology Group Phase II Study (ECOG 1504).
- Proteomic profiling of human plasma by iTRAQ reveals down-regulation of ITI-HC3 and VDBP by cigarette smoking.
- A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protec...
- Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies.
- Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung Cancer.
- Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung Cancer: a California Cancer consortium trial.
- Phase II study of everolimus (RAD001) in previously treated small cell lung Cancer.
- Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
- A phase 1 study of BMS-275183, a novel Oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.
- Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung Cancer (National Ca...
- Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid Tumors.
- Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: R...
- Maintenance therapy for advanced non-small cell lung Cancer: current status, controversies, and emerging consensus.
- Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advan...
- Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung Cancer.
- Antiangiogenic agents in the treatment of nonsmall cell lung Cancer: reality and hope.
- Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung Cancer cells.
- Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung Cancer.
- Novel cytotoxic agents.
- Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced Malignancies.
- Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced Malignant pleural mesothelioma.
- Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung Cancer: a multicenter phase 2 study.
- Recent advances in the treatment of Malignant pleural mesothelioma.
- Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular Cancer: a California Cancer Consortium Trial.
- Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for ...
- A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid Malignancies.
- Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refra...
- Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung Cancer.
- Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patient...
- Lung Cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database.
- Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refra...
- Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung Cancer.
- Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid Malignancies.
- Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of Cancer: a controlled, randomized, open-label phase II trial.
- A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid Tumors.
- Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of ...
- Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced Cancers.
- Radiosurgery for the treatment of spinal Lung metastases.
- PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung Cancer and perform...
- Treatment of elderly non-small cell lung Cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomiz...
- Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advance...
- Optimizing chemotherapy for advanced non-small cell lung Cancer: focus on docetaxel.
- Multivariate analysis of survival, local control, and time to distant metastases in patients with unresectable non-small-cell lung Carcinoma treated with 3-dimensional...
- Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung Cancer: a randomized phase II locally advanced multi-modalit...
- Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
- Molecular predictors of sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor: confusion or clarity?
- Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients ...
- Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung Cancer receiving gefitinib in a randomized controlled trial.
- The ANITA trial seals the deal for adjuvant therapy in non-small-cell lung Cancer.
- Adjuvant and neoadjuvant therapy in non-small cell lung Cancer.
- Bevacizumab extends survival for patients with nonsquamous non-small-cell lung Cancer.
- Optimizing first-line treatment options for patients with advanced NSCLC.
- Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
- Emerging advances in the management of lung Cancer.
- Emerging role of erlotinib (OSI-774) in non-small-cell lung Cancer.
- Recent updates in the clinical use of platinum compounds for the treatment of lung, Breast, and genitourinary tumors and myeloma.
- Radiofrequency ablation: identification of the ideal patient.
- Combining targeted agents in lung Cancer.
- Challenges in advanced NSCLC: optimizing platinum-based chemotherapy and treating special populations.
- Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid Tumors.
- Neoadjuvant versus adjuvant therapy for resectable non-small-cell lung Cancer.
- Carboplatin/gemcitabine combination in advanced NSCLC.
- Epidermal growth factor receptor mutations: a new insight.
- Smoking cessation and treatment outcome.
- State-of-the-art chemotherapy for advanced non-small cell lung Cancer.
- Basic treatment considerations: chemotherapy.
- Cyclooxygenase-2 inhibitors in lung Cancer.
- Lung Cancer: looking ahead in 2004.
- Clinical lung Cancer indexed in Index Medicus and Medline.
- Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung Cancer: a randomized trial.
- Results of clinical trials for locally advanced and metastatic nonsmall-cell lung Cancer.
- Elderly patients with advanced non-small-cell lung Cancer.
- Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung Cancer: the TAX 3...
- Multicenter, randomized trial for stage IIIB or IV non-small-cell lung Cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or obse...
- Early-stage non-small-cell lung Cancer: adjuvant versus neoadjuvant chemotherapy.
- Gefitinib for non-small cell lung Cancer: is the efficacy real?
- Antinsense oligonucleotides in lung Cancer: do they really make sense?
- Adjuvant therapy for surgically resected non-small-cell lung Cancer: will it become a reality?
Schools
Sawai Mansingh Medical College Jaipur
Good SamaritanU MD Hosps
North Genl HospMt Sinai Ho
Sms Med Hospital
University MD Hospital
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Pittsburgh Magazine
Education
-
University of Maryland -
Sawai Man Singh Medical College
Hospital
-
Penn State Milton S. Hershey Medical Center
Drug Facts
| NPI NUMBER | 1659343895 | |
| NPPES Provider LastName | BELANI | |
| NPPES Provider FirstName | CHANDRA | |
| NPPES Provider ZIPCode | 170332360 | |
| NPPES Provider State | PA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 49.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1659343895 |
| Last Name Of The Provider | BELANI |
| First Name Of The Provider | CHANDRA |
| View All |
Similar Doctors
|
|
Dr. Marc A. Rovito, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Giampaolo Talamo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ayodele G. Ayoola, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Raymond J. Hohl, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Elaine Eyster, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allan Lipton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mhd Y. Al-Marrawi, MD |
|
|
Dr. Julie A. Campbell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey J. Pu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Harold A. Harvey, MB
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|